
You can get low dose HRT online. A licensed clinician has to evaluate you first — that part is real, not a formality. But "low dose" is not one number.
Last updated: · Last verified: · Every price, dose, and label claim below is sourced and dated.
It’s a strength inside one specific product, and the numbers don’t transfer between products.
Four “low doses.” Four different products. You can’t compare them by looking at the numbers.
One more thing, from the FDA’s own trial data:
The lowest dose of Divigel didn’t clearly beat a sugar pill until week 7. Not week 2. Week 7. That number changes what you should be asking a provider.
These timing factors make the conversation more favorable. They don’t decide it for you.
Unexplained bleeding especially. The label requires ruling out cancer before systemic estrogen. Not “consider.” Requires.
The right online HRT provider isn’t the same for every woman — it depends on your symptoms, your age, whether you have a uterus, your route preference, your risk history, your insurance or cash-pay situation, and your state.
Find My HRT Path →The HRT Index is the independent decision resource for online menopause and HRT care — comparing providers on clinical legitimacy, care quality, medication fit, price transparency, and access.
“Low dose” is not an FDA category. It refers to a lower marketed or labeled strength within one specific product, and those strengths cannot be compared across products.
Estradiol is the main estrogen your ovaries used to make. Systemicmeans it circulates through your whole body — that’s the kind that touches hot flashes. If you have a uterus, it’s usually estrogen plus a progestogen.
Published sources contradict each other — some call 1 mg oral “low dose,” others call 0.5 mg “low dose.” Those definitions don’t even overlap. So we stopped reading health sites and went to the labels.
Not equivalent doses. Not a self-start guide.
| Product type | Labeled strength example | Labeled for | Watch out |
|---|---|---|---|
| Once-weekly estradiol patch | 0.025 mg/day | Some labels start vasomotor-symptom treatment here | Product-specific. Don’t assume every patch |
| Twice-weekly estradiol patch | 0.0375 mg/day | Some labels start vasomotor-symptom treatment here | 0.025 mg/day may be the osteoporosis-prevention dose on these, not the hot flash dose |
| Menostar patch | 0.014 mg/day | Osteoporosis prevention only | Not labeled for hot flashes. See section below |
| Divigel (estradiol gel) | 0.25 mg | Labeled starting dose for hot flashes | The one product with a published week-by-week curve |
| Oral estradiol tablet | 0.5 mg is a marketed strength | One generic label states a usual initial hot flash dose of 1–2 mg daily | 0.5 mg exists — it isn’t the universal labeled starting dose |
| Bijuva (estradiol + progesterone) | 0.5 mg / 100 mg | Labeled starting strength | Specific to Bijuva. Doesn’t transfer to separate pills |
| Premarin (conjugated estrogens) | 0.3 mg | Generally starts hot flash treatment here | Product-specific. Not every conjugated estrogen starts here |
Sources: FDA and DailyMed prescribing information for each product. Accessed July 14, 2026.
A once-weekly patch and a twice-weekly patch can have completely different labeled starting doses for the same symptom. On some twice-weekly patches, 0.025 mg/day is the bone dose, and hot flash treatment starts at 0.0375.
Ask this instead: “What’s the labeled starting dose for hot flashes on the exact patch you’re prescribing me?”
A 0.025 mg patch and a 0.5 mg pill look wildly different. A patch goes through your skin, straight into your blood. A pill goes through your stomach and liver first (first-pass metabolism) and much is processed before reaching the rest of you. The numbers on the boxes are measuring different things.
The number on the box isn’t the amount that reaches your body. Compare within a product line. Never across.
Menostar delivers 0.014 mg of estradiol per day — the lowest-dose estradiol patch sold in the U.S. Its labeled indication is prevention of postmenopausal osteoporosis. It is not FDA-labeled to treat hot flashes.
If you go hunting for the lowestdose, you can land on Menostar. Real product. Real FDA approval. Smallest number on the shelf. Prescribing it for hot flashes would be off-label — and the osteoporosis indication doesn’t establish that it works for hot flashes, because that’s not what it was approved on.
So if it doesn’t help your hot flashes, that tells you nothing about whether HRT would. You’d be judging systemic hormone therapy on a product that was never labeled to do the thing you wanted done.
If someone offers you the 0.014 mg patch for hot flashes, ask why. There may be a good reason. You should hear it.
In February 2026, FDA approved labeling changes to six menopausal hormone therapy products, removing boxed-warning language about cardiovascular disease, breast cancer, and probable dementia. It retained the boxed endometrial cancer warning for systemic estrogen-alone products. It did not declare hormone therapy safe for everyone.
Our one honest admission — and it’s about the news, not a provider
The FDA did not say hormone therapy is safe.A lot of pages are telling you it did. Section 5.1 of the updated Divigel label still describes increased risk of blood clots and stroke. That information didn’t disappear — it moved out of the boxed warning and into the regular warnings section.
What the Menopause Society actually said is specific: risks are low for younger, healthy women starting closer to the menopause transition, and greater for older women further out. That’s more useful than “it’s all fine now.”
FDA asked 29 companies to submit changes. As of , six products had been approved. FDA’s tracking page is still marked “content current as of 02/12/2026.”
| Product | Category |
|---|---|
| Divigel (estradiol gel) | Systemic estrogen alone |
| Cenestin (synthetic conjugated estrogens A) | Systemic estrogen alone |
| Enjuvia (synthetic conjugated estrogens B) | Systemic estrogen alone |
| Bijuva (estradiol + progesterone) | Systemic combination |
| Prometrium (progesterone) | Progestogen alone |
| Estring (estradiol vaginal ring) | Topical vaginal |
Source: FDA, “Menopausal Hormone Therapies with Updated Prescribing Information.” Content current as of 02/12/2026. Accessed .
So here’s what may happen to you
You read that the FDA removed the scary warning. You get prescribed a patch. You open the box. And there’s the old warning — breast cancer, dementia, heart disease — right there in your hand at 9pm.
Nothing went wrong.Labels are updated product by product, manufacturer by manufacturer. FDA approved the first six in February. Most haven’t come through yet. The label in your box is the one that legally applies to your medication.
Dose is one of several interacting factors affecting benefit and risk. Route may affect thrombotic risk because transdermal estradiol avoids first-pass hepatic metabolism. Progestogen status determines endometrial risk if you have a uterus. Timing — how long since menopause — is an important part of the assessment.
You think dose is the safety dial. It’s one dial among several, and the others aren’t quieter.
| The factor | What it affects |
|---|---|
| Dose | Symptom relief and how fast. Endometrial risk from unopposed estrogen rises with dose and duration. |
| Route (patch vs. pill) | May affect clot risk. Transdermal avoids first-pass liver metabolism — that's the biologic reason. |
| Progestogen | Endometrial risk, if you have a uterus. Needed with systemic estrogen regardless of how low the dose is. |
| Timing | An important part of the benefit-risk assessment. Now on updated labels. |
| Your history | Whether systemic hormone therapy is an option at all. |
Make it concrete.
Picture two women. One takes a low dose of oral estrogen, started at 66, fifteen years after menopause. The other takes a standard-dose patch, started at 51.
Dose alone cannot tell you which of those is the safer situation. She picked the smaller number. Not the safer one. Those aren’t the same decision.
If you take one thing from this page:ask about route and timing with the same energy you’re bringing to dose.
Under 60. Within 10 years of your last period. No history of clots or breast cancer. Tired of being told to ride it out.
You’re not early. You’re on time.
Find My HRT Path →Answer a few questions and get a plan you can bring to a consult, including a flag if online care isn’t your right first step.
Low-dose vaginal estrogen targets genitourinary symptoms — dryness, irritation, painful sex — with low, product-specific systemic exposure. Systemic HRT is what’s labeled for hot flashes and night sweats.
We’re putting this here because some of you are about to buy the wrong thing.
| What’s actually bothering you | Likely discussion | Where to go |
|---|---|---|
| Hot flashes, night sweats, waking up soaked | Systemic — patch, pill, or gel | Keep reading |
| Dryness, burning, sex hurts, recurring UTIs — mostly that | Local vaginal estrogen | Vaginal estrogen guide → |
| Both | Could be either or both. Needs a real conversation | Find My HRT Path → |
| Complex history | In-person assessment first | See in-person section below |
Two things worth knowing:
Vaginal estrogen generally doesn’t need a progestogen. The Menopause Society doesn’t recommend adding one with recommended low-dose vaginal estrogen.
The Menopause Society explicitly supported removing the boxed warning for low-dose vaginal estrogen — its language was that the warning may have deterred women from a safe and effective therapy for a condition most menopausal women get.
If the dryness/irritation row is you — go. Vaginal estrogen guide. We’d rather lose you to the right page than convert you onto the wrong drug.
If you have a uterus and use systemic estrogen, the regimen generally needs adequate endometrial protection — at any dose, including the lowest. This is the boxed warning the FDA retained in 2026.
Progestogen is the family of medications that protects your uterine lining from estrogen. Progesterone is the specific member that matches what your body made.
If you have a uterus and you’re on systemic estrogen, you need endometrial protection. Not at higher doses only. Systemic estrogen without it can increase the risk of endometrial hyperplasia and cancer. That’s why the FDA kept this one warning when it deleted the others.
The progesterone capsule label’s regimen for endometrial protection is 200 mg at bedtime for 12 days per 28-day cycle, alongside daily conjugated estrogen. That’s what’s approved for that indication.
100 mgis a real capsule strength, and 100 mg daily is what’s inside Bijuva — an approved combination product. Many clinicians also prescribe 100 mg daily continuously. That’s common practice. But common practice and the labeled regimen aren’t the same thing. Ask which one you’re being given.
If you’ve had a hysterectomy, you generally don’t need a progestogen. But if you have a history of endometriosis, say so at your consult — Divigel’s updated label notes some women without a uterus but with endometriosis history may benefit from one.
See also: HRT after hysterectomy.
In the Divigel trial, the 0.25 mg dose did not reach statistical significance versus placebo on hot flash frequency or severity at week 4. Both reached significance by week 7. This result is specific to Divigel 0.25 mg and does not establish a timeline for any other product, route, or individual.
The trial: 495 postmenopausal women. Median age 54.6. Every one having at least 50 moderate-to-severe hot flashes a week. Randomized, placebo-controlled.
| Divigel dose | Week 4 frequency | Week 4 severity | Week 7 | Median severity change at week 12 |
|---|---|---|---|---|
| 0.25 mg (lowest) | ✕ p=0.132 | ✕ p=0.283 | ✓ Both significant | −0.33 |
| 0.5 mg | ✓ p=0.011 | ✓ p<0.001 | ✓ Both significant | −0.56 |
| 1.0 mg | ✓ p<0.001 | ✓ p<0.001 | ✓ Both significant | −1.69 |
| Placebo | — | — | — | −0.13 |
The two mistakes
Quitting at week 3.No clear improvement by week 3 doesn’t establish that a lowest dose has failed. On Divigel 0.25 mg, week 3 is before the data showed separation at all. You’d be quitting on a question that hadn’t been answered yet.
Assuming week 12 is the ceiling.If symptoms are still disruptive at follow-up, that’s information — not a verdict. It might mean the dose, the route, adherence, a side effect, or something else. It means go back and say so.
Low dose is a starting point. It’s only a destination if it actually works.
| Divigel dose | Average level | Variation between participants |
|---|---|---|
| 0.25 mg | 9.8 pg/mL | 92% |
| 0.5 mg | 21 pg/mL | 148% |
| 1.0 mg | 30.5 pg/mL | 81% |
That last column is the coefficient of variation. The same dose produced substantially different measured exposure in different women.That’s FDA data. The label goes further: serum estrogen concentrations do not predict an individual woman’s response to Divigel.
Also from the label (Section 5.20): serum FSH and estradiol levels have not been shown useful in managing moderate-to-severe hot flashes. If someone wants to sell you a hormone panel to pick your hot flash dose, that’s not what the label supports. Ask why.
Current guidance emphasizes the lowest effectivedose, individualized duration, and periodic reevaluation — not an automatic rule to keep every woman at the lowest marketed strength or stop at a fixed date. FDA’s 2025 requested labeling changes removed “lowest effective dose for the shortest amount of time” from the boxed warning.
2002. The Women’s Health Initiative published early results and the world panicked. The average woman in that trial was 63 — older than the age at which many women start treatment for hot flashes. Findings from that population got applied to healthy 51-year-olds who looked nothing like them.
Dr. Samantha Dunham(NYU Langone Health Center for Midlife Health and Menopause, HealthCentral, March 2026): the field is moving away from “low and slow — the lowest dose of estrogen for the shortest time.”
Dr. Stephanie Faubion(The Menopause Society / Mayo Clinic Center for Women’s Health): hormone therapy is the most effective treatment for menopause symptoms, and it’s vastly underutilized. Fewer than 4% of U.S. women ages 50–59 used hormone therapy in the cited data.
Dr. Lisa Larkin (San Antonio Breast Cancer Symposium, December 2025, Breastcancer.org, January 2026): flagged particular concern about messaging that overemphasizes benefits and minimizes risks for breast cancer survivors, where the data is genuinely unclear.
Low dose HRT is a real option for a specific woman under specific conditions. That’s a better story than “it’s all fine now,” and it has the advantage of being true.
The short-term evidence that low doses relieve symptoms is solid. The long-term outcome data at those specific doses over many years is thinner than at standard doses. That’s not a reason to avoid low dose — it’s a reason to keep a real clinician involved rather than treating this as set-and-forget.
Age alone isn’t a disqualifier, but it changes the conversation. Updated labeling says to consider starting systemic HRT in women under 60 or within 10 years of menopause onset. Some online providers set their own age limits regardless.
It’s not a no.The FDA’s language is “consider” — it identifies a window where the balance is more favorable, not a wall.
Two things change:
The clinical conversation gets more individualized. Risks are greater when hormone therapy is initiated in older women and in those further from menopause onset. That doesn’t end the discussion — it means a longer one, probably in person.
Some providers won’t see you at all. Winona states it provides HRT treatment plans only to women ages 35–59.If you’re 60, that’s a business policy — and you’ll find out at intake.
If you’re over 60: Midi and Sesame both offer live video visits. If your history is at all complicated, an in-person clinician who can order what they need is the better starting point.
Asks your age and flags provider restrictions before you waste a consult fee.
Most online menopause providers can prescribe low-dose HRT. They differ on two things that matter more than the monthly price: whether they prescribe FDA-approved finished products or compounded formulations, and what they publish about follow-up and dose adjustment.
Given what the Divigel data showed, this is the table we’d want if we were you.
| Provider | First check-in | Messaging | Live video? | Guaranteed response time |
|---|---|---|---|---|
| Midi Health | Live initial and continued-care visits; platform messaging | ✓ Yes | ✓ Yes, 30-min initial | Not published. Confirm how dose changes are handled between visits |
| Sesame | Video visits as needed | ✓ Unlimited | ✓ Yes — you pick the provider | Not published. Advertises easy treatment adjustments |
| Winona | Provider-stated 10-week check-in | ✓ Secure portal, included | ✕ Async only | Not published. Portal access ≠ guaranteed clinician response time |
| Hers | Regular check-ins, timing not publicly specified | ✓ Unlimited provider messaging | Not verified | Not published |
| Inner Balance | Unresolved — their own pages conflict | ✓ Unlimited follow-up claimed | Not verified | Not published |
Compiled from each provider’s published materials. Accessed . Cells marked “not published” mean we could not find an official source, not that no policy exists.
Notice what’s missing from every row. Not one of these providers publishes a guaranteed turnaround for a dose change. That’s not a knock — it’s an industry norm. The provider who gives you a straight answer at intake is telling you something.
Compounded formulations don’t have dose-response data at their custom strength. ACOG’s position is that compounded menopausal hormone therapy shouldn’t routinely be prescribed when FDA-approved formulations exist. That’s why the low-dose question is the one where FDA-approved products matter most. Our compounded vs. FDA-approved guide →
Strongest first comparison for in-network PPO members
The punchline: Live video with a clinician, prescribes FDA-approved hormone options, in network with most major PPOs, and your prescription goes to your own pharmacy — so your insurance can apply to the medication too.
Published pricing:$250 initial self-pay visit, generally $150 for continued care. With an accepted PPO, you’d pay your plan’s cost-sharing instead.
Best for you if:
Not for you if:
Those exclusions aren’t small. If Medicare or Medicaid is you, go to Sesame — it doesn’t bill insurance at all, so there’s nothing to be excluded from.
What a patient said: “Midi was so easy: I got a same day appointment and they took my insurance.” — Published by Midi, not independently verified by us. Not a claim about typical results.
Check whether Midi is in-network with your plan →Cash-pay care with a local-pharmacy prescription
The punchline:$59/month care subscription. Video visits with a provider you choose, unlimited messaging, basic lab work included if your provider determines it’s necessary, and your prescription goes to your local pharmacy. Medication is separate.
Best for you if:
Not for you if:
What a patient said: “the first provider happily willing to go through the research and my concerns.” — Published by Sesame, not independently verified by us.
See Sesame’s current $59 care subscription →Bundled and shipped, with real limits you need to know first
Read these three things before anything else:
The punchline: One price, one box, shipped. The estradiol patch is $149/month with the consult, secure portal messaging, and shipping included. A 10-week check-in is scheduled.
On FDA approval — the distinction is real:
Best for you if:
Not for you if:
On price, honestly.Winona’s patch is $149/month, everything in. Published cash-price data lists generic estradiol transdermal patches, 0.025 mg/24hr twice-weekly, at approximately $36 for a 30-day supply of 8 patches before insurance. That’s a real gap — but Winona’s price includes the consult, messaging, and shipping, and we haven’t verified that Winona dispenses that same manufacturer’s patch. Check yours before you assume either number applies.
Check Winona’s age and state eligibility →Lower monthly-equivalent pricing, with a 12-month commitment
The punchline: Estradiol and progesterone treatment from $79/month oral or $134/month for the patch — both figures are monthly-equivalent on a 12-month plan.
One thing Hers discloses that almost nobody else does: Hers states its hormone replacement regimens are not FDA-approved specifically for treating perimenopause, and may be prescribed off-label for perimenopausal symptoms at a clinician’s discretion. If you’re still having periods, that applies to you — and the fact that Hers says so while competitors don’t is worth noticing.
Best for you if:
Not for you if:
Compounded, with unresolved questions
The punchline: Estradiol and progesterone compounded into a single daily cream. Published pricing roughly $199/month for the first six months, then around $99.50/month. The finished Oestra product is compounded and is not FDA-approved.
Three things we could not resolve:
We have not independently substantiated Inner Balance’s claims about absorption, side effects, whole-body results, endometrial protection, or its compounding category. Treat those as marketing until they’re verified. And don’t assume compounded vaginal progesterone provides endometrial protection equivalent to an FDA-approved regimen.
Review Oestra’s compounded-product status and current terms →Find your row. One action each — you’ve already done the comparing.
| This sounds like me | Start with | Confirm before you pay |
|---|---|---|
| PPO insurance, want a real video visit | Midi Health → | Network status, cost-sharing, formulary, between-visit dose changes |
| Paying cash, want a local pharmacy | Sesame → | What labs are included, provider availability |
| Medicare or Medicaid | Sesame → | Sesame doesn’t bill insurance — confirm cash-pay with your clinician |
| 35–59, in a listed state, want it shipped | Winona → | Your state, the 24-hour cancellation window, the exact patch product |
| Route settled, want lowest monthly-equivalent | Hers → | The 12-month terms, your state, the exact product |
| Specifically want one compounded cream | Inner Balance → | Your state, which pharmacy, follow-up cadence |
| 60 or older | Live video — Midi or Sesame | Winona won’t treat you. Consider in-person if history is complex |
| Only vaginal symptoms | Vaginal estrogen guide → | You may not need systemic at all |
| Honestly not sure | Find My HRT Path → | Answer the safety questions honestly |
State availability differs by provider and changes. Midi states it operates in all 50 states. Winona lists 37 states plus Puerto Rico. Hers states menopause care isn’t available in all 50 states without publishing a complete list. Inner Balance’s own pages conflict. Confirm your state on the provider’s current eligibility flow before paying.
This is the fastest way to waste a consult fee, so check it first.
| Provider | Published state coverage | Status |
|---|---|---|
| Midi Health | States all 50 states | Provider-stated |
| Sesame | Marketplace model; provider availability varies | Check your state in their flow |
| Winona | 37 states plus Puerto Rico | Provider-stated, published list |
| Hers | "Not available in all 50 states" — no complete public list found | Unresolved |
| Inner Balance | Their own pages say both 50 + D.C. and 43 + D.C. | Unresolved — conflicting official sources |
Accessed . State lists change. Verify in the provider’s current eligibility flow.
Find My HRT Path asks your state first — so you don’t get to checkout before finding out.
There’s no single lab rule. Divigel’s label states that serum FSH and estradiol levels have not been shown useful for managing moderate-to-severe hot flashes. Clinicians may still order labs for other diagnostic or safety reasons.
“Do I need labs to prove I’m in menopause?” No test confirms perimenopause. Hormone levels swing day to day.
“Do I need labs before starting HRT?” Maybe — but not to pick your hot flash dose. Your clinician may want labs to check other causes or for safety reasons specific to your history.
| Provider | Published lab position |
|---|---|
| Midi Health | May order blood work or imaging as the clinician determines. Exact included-lab policy not verified. |
| Sesame | Basic lab work included if the selected provider determines it's necessary, subject to program terms. |
| Winona | States bloodwork isn't required to be prescribed a treatment plan. |
| Hers | Not publicly specified. |
| Inner Balance | Not publicly specified. |
Accessed .
Ask: Are labs required for me or just available? Included in the price? Can I use recent results? What happens if something comes back needing in-person follow-up?
Cancellation terms differ sharply and are rarely on the pricing page. Winona allows full refund only within a mandatory 24-hour order processing window. Hers’ general terms require cancellation at least two days before the renewal processing date. Confirm at checkout.
Nobody reads this until they need it. Read it now.
| Provider | What we found |
|---|---|
| Winona | Full refund only during the 24-hour order processing window. After that, prepared prescription orders can't be cancelled or refunded. Subscription can be cancelled for future refills. |
| Hers | General terms: cancellation effective at end of current period, submitted at least 2 days before renewal processing. Confirm the menopause plan uses this term. |
| Midi Health | Fee-for-service visits — no subscription to cancel. |
| Sesame | Monthly subscription — confirm cutoff at checkout. |
| Inner Balance | States "cancel anytime." Confirm the cutoff, refund treatment, and what happens to an order already at the pharmacy. |
Accessed .
One thing worth understanding about the two models. If your prescription goes to your own pharmacy (Midi, Sesame), it’s yours — you can generally transfer it, and leaving the platform doesn’t strand your medication. If it’s bundled and shipped, leaving means starting over somewhere else. That’s not a reason to avoid bundled care. It’s a reason to know which one you picked.
Online HRT has separate care, medication, lab, shipping, and plan-length costs. Published care fees range from Sesame’s $59/month subscription with medication separate, to Midi’s $250 initial and $150 continued self-pay visits. Bundled plans that include medication publish monthly-equivalent prices from approximately $79 upward.
Two structurally different models. Most pages blur them.
You can apply insurance or a discount card to the medication.
| Provider | Care cost | Medication | Insurance? |
|---|---|---|---|
| Midi Health | Your PPO cost-sharing, or $250 initial / $150 continued self-pay | Separate — at your pharmacy | ✓ Most PPOs · ✕ Medicare · ✕ Medicaid |
| Sesame | $59/month subscription | Separate — at your pharmacy | ✕ Doesn’t bill insurance |
Medication included. Insurance generally doesn’t apply.
| Provider | Published monthly | Product status |
|---|---|---|
| Winona — estradiol patch | $149 | FDA-approved per Winona; exact finished product not identified |
| Winona — E+P cream | from $89 | Compounded — not FDA-approved |
| Hers — patch | from $134 (12-month plan) | Exact finished product not identified |
| Hers — oral | from $79 (12-month plan) | Exact finished product not identified |
| Inner Balance | ~$199 → ~$99.50 after 6 months | Compounded — not FDA-approved |
Provider pricing from each company’s published materials. Accessed .
90 days: an intake, a few fills, and an early follow-up — the window where you learn something.
| Item | Midi (PPO) | Sesame (cash) | Winona (patch) |
|---|---|---|---|
| Care — confirmed | Cost-sharing per your plan | $59 × 3 = $177 | Included |
| Medication | Separate — varies | Separate — varies | Included |
| Follow-up | Cost-sharing | Included | Included |
| Labs | If ordered — varies | Included if provider determines necessary | Not required per Winona |
| Shipping | n/a | n/a | Included |
| Commitment | None | Monthly | Per order; 24-hr cancel window |
| 90-day care total | Cost-sharing only | $177 + medication | ~$447 all-in |
As of , published cash-price data lists generic estradiol transdermal patches, 0.025 mg/24hr twice-weekly, at approximately $36 for a 30-day supply of 8 patchesbefore insurance. That’s one snapshot from one source. Look yours up before you build a budget on it.
Brand vs. generic.Brand-name patches can run several times the generic cash price. If a generic won’t stay on through a shower, it isn’t cheaper — it’s useless. Ask your prescriber whether a generic is a fit for your situation.
Insurance or a discount card — usually one or the other.A pharmacy claim generally processes either through your insurance or as a cash/coupon transaction. With a high deductible, the cash price sometimes beats the copay — ask your pharmacist to check both. One catch: a cash purchase typically doesn’t count toward your deductible.
We check this so you don’t have to. When claims don’t reconcile, we publish that instead of picking one and hoping.
| What’s unresolved | What we found | What it means for you |
|---|---|---|
| Winona's patch product | Winona states the estradiol patch is FDA-approved. The public page doesn't name the finished product or manufacturer. | Provider-stated, not independently verified. Ask for the product name at intake. |
| Hers' products | Lists estradiol and progesterone. Exact finished products and manufacturers not identified publicly. | Ask before you commit to 12 months. |
| Inner Balance's pharmacy | Their own pages say both 503A pharmacy and 503B outsourcing facility. | Different regulatory categories. We won't publish either until they say which. |
| Inner Balance's states | Their own pages say both 50 + D.C. and 43 + D.C. | Confirm your state at source. |
| Inner Balance's follow-up | One official article says month 4 before raising a dose. Another says monthly. | On a page about who follows up, that's the whole question. |
| Hers' state list | States 'not all 50' — no complete public list found. | Don't assume. Check. |
| Every provider's response time | Not one publishes a guaranteed turnaround for a dose change. | Ask at intake. The answer tells you a lot. |
Accessed .
Why we publish this instead of smoothing it over: because you’re about to give one of these companies your medical history and your credit card. You should know exactly which claims we could stand behind and which we couldn’t.
Free. No email. Screenshot it.
Number 9 is the one nobody asks. Ask it. You know why now.
Two warnings on number 4:
Ask it as a yes/no: “Is this finished product FDA-approved?”
Online care isn’t the right starting point for every woman. Undiagnosed abnormal genital bleeding, a history of breast cancer or blood clots, liver disease, pregnancy, or significant diagnostic uncertainty may require in-person evaluation, examination, or imaging before any systemic hormone prescription is appropriate.
We’d rather lose the click than get this wrong.
Start in person if you have:
Also worth starting in person:a breast lump or anything you’d want examined, symptoms nobody’s explained, or a complicated history where you want everything in one chart.
Emergency symptoms — chest pain, sudden shortness of breath, one-sided leg swelling, vision changes, sudden severe headache — call 911 or go now. Not an online form.
Find My HRT Path flags when online care isn’t your right first step and gives you a question list to bring to a clinician instead. No provider links in this section. On purpose.
✓ Sources accessed :
✕ What we did NOT do:
How we do it: The HRT Index Verification Standard — read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule (top providers monthly, full roster quarterly).
Our five pillars, in order:clinical legitimacy · care quality · medication fit · price transparency · access. No scores. No stars. A number can’t tell you whether a provider fits your life.
Found something wrong? Tell us. We’ll check it and date the correction.
Low dose is a fine place to start. It’s only a destination if it works. The labeled starting strengths are real, evidence-backed places to begin. But the FDA’s own data shows the lowest dose of one gel took seven weeks to separate from placebo, moved severity less than higher doses, and produced very different measured exposure in different women. Most products don’t even publish that much.
So the thing that determines whether this works for you isn’t the dose you start on. It’s whether anyone checks. Pick a provider on that. Not on the monthly number.
Educational only. Find My HRT Path doesn’t diagnose anything, doesn’t recommend a dose, and doesn’t replace a licensed clinician. Because it asks about your health, we handle your answers under our consumer health data and privacy policy.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.